Capital Investment Advisory Services LLC Sells 1,646 Shares of Johnson & Johnson (NYSE:JNJ)

Capital Investment Advisory Services LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 5.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,906 shares of the company’s stock after selling 1,646 shares during the period. Capital Investment Advisory Services LLC’s holdings in Johnson & Johnson were worth $4,470,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of JNJ. Lewis Asset Management LLC grew its position in Johnson & Johnson by 6.1% in the fourth quarter. Lewis Asset Management LLC now owns 4,889 shares of the company’s stock worth $707,000 after acquiring an additional 282 shares in the last quarter. Busey Bank grew its position in Johnson & Johnson by 2.2% in the fourth quarter. Busey Bank now owns 267,386 shares of the company’s stock worth $38,669,000 after acquiring an additional 5,683 shares in the last quarter. First Affirmative Financial Network grew its position in Johnson & Johnson by 3.1% in the fourth quarter. First Affirmative Financial Network now owns 7,543 shares of the company’s stock worth $1,091,000 after acquiring an additional 227 shares in the last quarter. Synergy Asset Management LLC grew its position in Johnson & Johnson by 116.2% in the fourth quarter. Synergy Asset Management LLC now owns 12,734 shares of the company’s stock worth $1,940,000 after acquiring an additional 6,844 shares in the last quarter. Finally, Drystone LLC purchased a new position in Johnson & Johnson in the fourth quarter worth $2,893,000. 69.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $152.09 on Monday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market cap of $366.17 billion, a P/E ratio of 22.87, a PEG ratio of 2.43 and a beta of 0.51. The firm has a 50-day moving average of $147.61 and a 200 day moving average of $156.13. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on JNJ shares. Bank of America lowered their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Barclays boosted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Raymond James lowered their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Citigroup lowered their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $170.44.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.